{arrow_up} Back to top

Risk Minimisation Materials

Search by company, common medicine name, or title of Risk Minimisation Material

Abacavir

Aurobindo Pharma - Milpharm Ltd.

{pdf_link}

Abacavir - Patient Alert Card

{healthcare_pro_orange} For Healthcare Professionals

Patient alert card for medicines containing Abacavir. This patient alert card should be used by patients who have been prescribed medicines containing Abacavir' and should carry with them at all times when taking this medicine.


{pdf_link}

Abacavir alert card

{healthcare_pro_orange} For Healthcare Professionals

Patient Alert Card


Dr. Reddy's Laboratories (UK) Ltd

{pdf_link}

Abacavir Alert Card

Important - Alert Card for Medicines Containing Abacavir.


Mylan

{pdf_link}

Abacavir Patient Alert Card

Abacavir Patient Alert Card


Abacavir+Lamivudine

Dr. Reddy's Laboratories (UK) Ltd

{pdf_link}

Abacavir Alert Card

Important - Alert Card for Medicines Containing Abacavir.


Aurobindo Pharma - Milpharm Ltd.

{pdf_link}

Abacavir alert card

{healthcare_pro_orange} For Healthcare Professionals

Patient Alert Card


{pdf_link}

Abacavir -Risk minimisation Brochure

{healthcare_pro_orange} For Healthcare Professionals

Abacavir hypersensitivity reaction Key risk minimisation points: Abacavir Hypersensitivity Reaction (HSR)


Amarox Limited

Ranbaxy (UK) Limited a Sun Pharmaceutical Company

{pdf_link}

Educational material

{healthcare_pro_orange} For Healthcare Professionals

Abacavir brochure risk minimisation


{pdf_link}

Patient alert card

Abacavir patient alert card


Abstral

Grunenthal Meds

{pdf_link}

Abstral - UK Patient and Carer guide

Important risk minimisation information, on Abstral (fentanyl citrate) sublingual tablet, for patients and their carers


{pdf_link}

Abstral - UK Prescriber Guide

{healthcare_pro_orange} For Healthcare Professionals

Important risk minimisation information, on Abstral (fentanyl citrate) sublingual tablet, for healthcare professionals


Acitretin

Morningside Healthcare Ltd

{pdf_link}

Patient Alert Card

Alert card to be distributed to all patients (male and female) each time the product is prescribed as a reminder of the required pregnancy prevention requirements/considerations.


{pdf_link}

Pharmacist Checklist - Guidance for dispensing Acitretin

{healthcare_pro_orange} For Healthcare Professionals

Guidance document for pharmacists including a background on the risks in addition to a list of information to be confirmed with the patient prior to dispensing.


{pdf_link}

'Prescriber Checklist/Acknowledgement Form for Prescribing Acitretin to Female Patients

Guidance document for pharmacists including a background on the risks in addition to a list of information to be confirmed with the patient prior to dispensing.


Genus Pharmaceuticals

{pdf_link}

Patient Reminder Card

{healthcare_pro_orange} For Healthcare Professionals

Alert card to be distributed to all patients (male and female) receiving acitretin each time the product is prescribed as a reminder of the required pregnancy prevention requirements/considerations.


{pdf_link}

Pharmacist Checklist - Guidance for Dispensing Acitretin

{healthcare_pro_orange} For Healthcare Professionals

Guidance document for pharmacists including a background on the risks of acitretin in addition to a list of information to be confirmed with the patient prior to dispensing.


{pdf_link}

Prescriber Checklist / Acknowledgement Form for Prescribing Acitretin to Female Patients

{healthcare_pro_orange} For Healthcare Professionals

Checklist/acknowledgement form for use when prescribing acitretin to female patients. This is intended to support discussion with the patient, present the key principles of the PPP and record that discussions have taken place by recording patient and prescriber signatures.


Aclasta

Sandoz Limited

{pdf_link}

Aclasta 5 mg solution for infusion - Patient Reminder Card

This Patient Reminder Card contains information regarding osteonecrosis of the jaw, a side effect that has been reported very rarely in patients receiving Aclasta. It also contains information regarding precautions that can be taken to reduce the risk of developing ONJ.


Acopair

Mylan

{pdf_link}

Guide For Healthcare Professionals - Important Risk Minimisation Information on Potential Risk of Medication Errors

{healthcare_pro_orange} For Healthcare Professionals

Guide For Healthcare Professionals - Important Risk Minimisation Information on Potential Risk of Medication Errors


Actiq

Teva Pharma B.V.

{pdf_link}

Teva UK Patient/Carer Guide to the Safe Use of ACTIQ®

Teva UK Patient/Carer Guide to the Safe Use of ACTIQ®


{pdf_link}

Teva UK Pharmacist's Guide for Dispensing ACTIQ®

{healthcare_pro_orange} For Healthcare Professionals

Teva UK Pharmacist's Guide for Dispensing ACTIQ®


{pdf_link}

Teva UK Physicians Guide for Prescribing ACTIQ®

{healthcare_pro_orange} For Healthcare Professionals

Teva UK Physicians Guide for Prescribing ACTIQ®


Agomelatine

Zentiva

{pdf_link}

Agomelatine Flow Chart

{healthcare_pro_orange} For Healthcare Professionals

Liver function monitoring scheme with Agomelatine for the treatment of major depressive episodes in adults


{pdf_link}

Agomelatine patient information guide

{healthcare_pro_orange} For Healthcare Professionals

Important information for patients about Agomelatine-recommendations to avoid liver side effects


{pdf_link}

Agomelatine prescriber guide

{healthcare_pro_orange} For Healthcare Professionals

Important safety information prescribers guide-Agomelatine- for the treatment of major depressive episodes in adults


Aristo Pharma Limited

{pdf_link}

Liver Function Monitoring Scheme with Agomelatine

{healthcare_pro_orange} For Healthcare Professionals

Liver function monitoring scheme with Agomelatine for the treatment of major depressive episodes in adults


{pdf_link}

Patient information. Recommendations to avoid liver side effects

Important information for Patients about Agomelatine. Recommendations to avoid liver side effects


{pdf_link}

Prescribers Guide

{healthcare_pro_orange} For Healthcare Professionals

Prescribers guide. Agomelatine for the treatment of Major Depressive Episodes in Adults


Akizza

Morningside Healthcare Ltd

{pdf_link}

Checklist for Prescribers - Akizza 75 mcg 30 mcg tablets

{healthcare_pro_orange} For Healthcare Professionals

Please use this checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations


{pdf_link}

Important Information leaflet - Akizza 75mcg/30mcg Tablets

All women should understand the small risk of blood clots with the combined hormonal contraceptives; what other conditions increase the risk of a blood clot; the signs and symptoms of a blood clot; when you need to tell a healthcare professional that you are using a combined hormonal contraceptive.


{pdf_link}

Patient Alert Card - Akizza 75mcg/30mcg Tablets

Important information for women about risk of blood clots with combined hormonal contraceptives.


Alitretinoin

Ennogen IP Ltd

{pdf_link}

Alitretinoin Patient Card

To be given by the dermatologist, specialist dermatology nurses, or prescribing GP to reinforce the key safety messages around risks


{pdf_link}

Alitretinoin Pharmacist Check List

{healthcare_pro_orange} For Healthcare Professionals

To be used as an aide memoire by pharmacists when dispensing oral retinoid medicines


{pdf_link}

Prescriber Checklist / Acknowledgement Form for Prescribing Alitretinoin to Female Patients

{healthcare_pro_orange} For Healthcare Professionals

To be used by the dermatologist, specialist dermatology nurse, or a prescribing GP with a special interest in dermatology to record the discussion of risks with the patient


Almuriva

Sandoz Limited

Alunbrig

Takeda UK Ltd

Alzest

Dr. Reddy's Laboratories (UK) Ltd

{pdf_link}

Alzest instructions for use and patient diary Dec 2020

Instructions for use and patient diary


Ambrisentan

Dr. Reddy's Laboratories (UK) Ltd

{pdf_link}

Ambrisentan Patient Reminder Card

{healthcare_pro_orange} For Healthcare Professionals

Patient Reminder Card for Ambrisentan


Mylan

{pdf_link}

Ambrisentan patient reminder card

Ambrisentan patient reminder card


Cipla EU Ltd

{pdf_link}

Patient Alert Card - Ambrisentan 5 & 10 mg tab

This card contains important information about Ambrisentan. Please read this card carefully before starting your treatment with Ambrisentan. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. If you are a woman of child-bearing age read this information carefully. Ambrisentan may harm unborn babies conceived before, during or soon after treatment. You must not take Ambrisentan if you are pregnant. Women of reproductive potential must use reliable contraception whilst taking Ambrisentan. Ambrisentan may cause liver injury. This card is produced as a service to patients by Cipla.


Zentiva

{pdf_link}

Patient Reminder Card

Important information for all patients taking Ambrisentan


Amfexa

Medice UK LTD

{pdf_link}

Amfexa Checklist 1

{healthcare_pro_orange} For Healthcare Professionals

Checklist 1: checklist before prescribing Amfexa® 5 mg, 10 mg and 20 mg Tablets


{pdf_link}

Amfexa Checklist 2

{healthcare_pro_orange} For Healthcare Professionals

Checklist 2: checklist for monitoring of ongoing therapy with Amfexa® 5 mg, 10 mg and 20 mg Tablets


{pdf_link}

Amfexa Considerations

{healthcare_pro_orange} For Healthcare Professionals

Considerations when ending treatment with Amfexa ® 5 mg, 10 mg and 20 mg Tablets


{pdf_link}

Amfexa Introduction

{healthcare_pro_orange} For Healthcare Professionals

Due to the stimulant properties of dexamfetamine sulfate and the frequent presence of comorbidities associated with ADHD, it is important that dexamfetamine sulfate products be used consistently and only for the appropriate patients. The accompanying materials were developed by one of the dexamfetamine sulfate product manufacturers to facilitate awareness and adoption of recommendations for the use of dexamfetamine sulfate. It is recommended that these materials be used in conjunction with the SmPC for the individual product that is being prescribed.


{pdf_link}

Amfexa patient and carers information UK

{healthcare_pro_orange} For Healthcare Professionals

Information for parents and carers of patients prescribed Amfexa 5mg, 10mg and 20mgs tablets


{pdf_link}

Amfexa Pharmacist Information

{healthcare_pro_orange} For Healthcare Professionals

This sheet provides additional information for pharmacists on Amfexa® 5 mg, 10 mg and 20 mg Tablets (dexamfetamine sulfate).


{pdf_link}

Amfexa Physician Information

{healthcare_pro_orange} For Healthcare Professionals

A physician’s guide to prescribing Amfexa® 5 mg, 10 mg and 20 mg Tablets (dexamfetamine sulfate)


{pdf_link}

Boys 2-18 years growth chart

{healthcare_pro_orange} For Healthcare Professionals

This chart is mainly intended to assess the growth of school age boys. It combines data from the UK 1990 growth reference for children at birth and from 4 -18 years(1), with the WHO growth standard for children aged 2 years to 4 years(2). The growth of children under 2 years of age should be plotted on the more detailed UK-WHO 0-4 years growth charts.


{pdf_link}

Chart for ongoing monitoring during Amfexa®(dexamfetamine sulfate) treatment

{healthcare_pro_orange} For Healthcare Professionals

A form template according to prescribing information in more detail, growth, psychiatric and cardiovascular status should be regularly monitored


{pdf_link}

Girls UK Growth chart 2-18 years

{healthcare_pro_orange} For Healthcare Professionals

This chart is mainly intended to assess the growth of school age girls. It combines data from the UK 1990 growth reference for children at birth and from 4 -18 years(1), with the WHO growth standard for children aged 2 years to 4 years(2). The growth of children under 2 years of age should be plotted on the more detailed UK-WHO 0-4 years growth charts.


Amgevita

Amgen Ltd

{pdf_link}

AMGEVITA Patient reminder card - adult

This card has important safety information about AMGEVITA. To request a copy of the patient alert card please contact Amgen medical information on 01223 436441 or by email to [email protected].


{pdf_link}

AMGEVITA Patient reminder card - paediatric

This card has important safety information about AMGEVITA. To request a copy of the patient alert card please contact Amgen medical information on 01223 436441 or by email to [email protected].


Amiodarone

Ennogen Pharma Ltd

{pdf_link}

Patient Alert Card for Amiodarone Hydrochloride 200mg Tablets

Patient Alert Card for Amiodarone Hydrochloride 200mg Tablets


Apidra

Sandoz Limited

{pdf_link}

Apixaban 2.5mg & 5mg Prescribers Guide

{healthcare_pro_orange} For Healthcare Professionals

Apixaban 2.5mg & 5mg Prescribers Guide This educational material is provided to further minimize the risk of bleeding that is associated with the use of apixaban and to guide healthcare professionals in managing that risk.


{pdf_link}

Apixaban 5mg film-coated tablets patient alert card

Apixaban 5mg film-coated tablets patient alert card


{pdf_link}

Apixaban 5mg film-coated tablets patient alert card (large)

Apixaban 5mg film-coated tablets patient alert card (large)


{pdf_link}

Apixaban2.5mg and 5mg film-coated tablets - cover letter

{healthcare_pro_orange} For Healthcare Professionals

Apixaban2.5mg and 5mg film-coated tablets - cover letter Outlining the indications for apixaban and the availability of risk minimisation materials.


Apixaban

Sandoz Limited

{pdf_link}

Apixaban 2.5mg & 5mg Prescribers Guide

{healthcare_pro_orange} For Healthcare Professionals

Apixaban 2.5mg & 5mg Prescribers Guide This educational material is provided to further minimize the risk of bleeding that is associated with the use of apixaban and to guide healthcare professionals in managing that risk.


{pdf_link}

Apixaban 2.5mg film-coated tablets patient alert card

Apixaban 2.5mg film-coated tablets patient alert card


{pdf_link}

Apixaban 2.5mg film-coated tablets patient alert card (large)

Apixaban 2.5mg film-coated tablets patient alert card (large)


{pdf_link}

Apixaban2.5mg and 5mg film-coated tablets - cover letter

{healthcare_pro_orange} For Healthcare Professionals

Apixaban2.5mg and 5mg film-coated tablets - cover letter Outlining the indications for apixaban and the availability of risk minimisation materials.


Mylan

{pdf_link}

Apixaban Patient Alert Card

Apixaban Patient Alert Card


{pdf_link}

Apixaban Prescriber Guide

{healthcare_pro_orange} For Healthcare Professionals

Apixaban Prescriber Guide


axunio Pharma GmbH

{pdf_link}

Apixaban Prescriber Guide

{healthcare_pro_orange} For Healthcare Professionals

The educational pack is aimed at increasing awareness about the potential risk of bleeding/bleeding or thrombosis due to overdose or underdose during treatment with apixaban and providing guidance on how to manage that risk. This Prescriber Guide is not a substitute for the Apixaban Summary of Product Characteristics (SmPC). Please consult the SmPC for full prescribing information.


{pdf_link}

Patient Alert Card

The patient alert card is aimed at increasing awareness about the potential risk of bleeding during treatment with apixaban. Patients prescribed apixaban will receive a patient alert card in the medicinal pack with the package leaflet. Please carry the patient alert card with you at all times and show it to every healthcare professional including pharmacists.


Teva UK Limited

{pdf_link}

Apixaban Teva Patient Alert Card

Apixaban Teva Patient Alert Card


{pdf_link}

Apixaban Teva Prescriber Guide

{healthcare_pro_orange} For Healthcare Professionals

Apixaban Teva Prescriber Guide


Aranesp

Amgen Ltd

{pdf_link}

Instructions for use for the Aranesp SureClick pre-filled pen

This booklet contains the instructions for use presented in a larger format and is intended for patients/caregivers with diminished eyesight. To request a printed version of this A4 booklet please contact Amgen Medical Information on 01223 436441 or by email to [email protected]


{pdf_link}

Training Checklist for Self Administration - Pre-Filled Pen (Sureclick)®

{healthcare_pro_orange} For Healthcare Professionals

This checklist is designed to ensure the patient/caregiver has received sufficient training with a demonstration device to enable confident and competent self-administration of the Aranesp SureClick® pre-filled pen at home. To request a printed version of the Training Checklist please contact Amgen Medical Information on 01223 436441 or by email to [email protected]


Arava

SANOFI

{pdf_link}

ARAVA- Physician leaflet

{healthcare_pro_orange} For Healthcare Professionals

For hard copies please contact our medical information department at 0800 035 2525 or email [email protected]


{pdf_link}

ARAVA-Patient Leaflet

For hard copies, please contact medical information department at 0800 035 2525 or email [email protected].


Arikayce

Insmed Limited

{pdf_link}

Arikayce Patient Alert Card

Patient alert card to notify patients on the adverse events and the procedure to deal with them.


Aronix

Dr. Reddy's Laboratories (UK) Ltd

{pdf_link}

Aronix - Pharmacy Checklist

{healthcare_pro_orange} For Healthcare Professionals

a short guide to help pharmacists determine whether your patient is suitable for Aronix, or whether he should be seen by a doctor for further advice. Use of the checklist is optional, and pharmacists should use their professional judgement to decide when and how to use it.


{pdf_link}

Essential information for the supply of Aronix

{healthcare_pro_orange} For Healthcare Professionals

This document provides key information to facilitate the assessment as to whether to supply Aronix, it also provides information on erectile dysfunction, its causes, risk factors, co-morbid links,management, treatment options, Aronix product information and pharmacist role in supporting the man.


Aspaveli

Swedish Orphan Biovitrum Ltd

{pdf_link}

Aspaveli - Guide for Healthcare Professional

{healthcare_pro_orange} For Healthcare Professionals

Important Information to communicate to patients/caregivers prior to prescribing ASPAVELI (pegcetacoplan)


{pdf_link}

Aspaveli - Guide for Patient and Caregivers

This guide contains important information and safety considerations for pegcetacoplan, including the risk of serious infections (including meningitis) and guidance on self administration.


{pdf_link}

Aspaveli - Patient Card

Important information for patients taking Aspaveli (pegcetacoplan)


Assicco

Morningside Healthcare Ltd

{pdf_link}

Glycopyrronium Bromide Tablets Patient Alert Card

The patient alert card is an aid which helps to provide the patient’s caregiver with essential information on the administration of Glycopyrronium bromide tablets and the management and minimisation of side effects. It is important that this card is given to the treating doctor to record guidance on dosing.


Aubagio

SANOFI

{pdf_link}

Aubagio (teriflunomide) – Healthcare professional (HCP) – Education / Discussion Guide - Risk Minimisation Information for Healthcare Professionals

{healthcare_pro_orange} For Healthcare Professionals

At first prescription, the prescriber/healthcare professional (HCP) should discuss with the patient the risks described within the discussion guide. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]


{pdf_link}

Aubagio (teriflunomide) – Patient Card - Risk Minimisation Information for Patients

The Patient Card contains important safety information the patient needs to be aware of when receiving treatment with Aubagio (teriflunomide). At first prescription, the prescriber/healthcare professional (HCP) should provide the Patient Card. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]


You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?